Marker Therapeutics, Inc.

Monthly Archives: September 2016




TapImmune Announces Reverse Stock Split in Preparation for Proposed Uplisting to NASDAQ Capital Market

JACKSONVILLE, Florida, September 15, 2016 / TapImmune Inc. (TPIV), a clinical-stage immuno-oncology company specializing in the development of innovative peptide and gene-based immunotherapeutics and vaccines for the treatment of cancer and metastatic disease, announced today that its Board of Directors has approved a 1-for-12 reverse stock split of the Company’s authorized, issued, and outstanding common stock in preparation for its proposed listing of its common stock on the NASDAQ Capital Market.
Read More

TapImmune Issues Update: Multiple Phase 2 Trials, over $9 Million in New Funding & NASDAQ Uplisting Application

JACKSONVILLE, Florida, September 6, 2016 / TapImmune, Inc. (TPIV), a clinical-stage immuno-oncology company specializing in the development of innovative peptide and gene-based immunotherapeutics and vaccines for the treatment of cancer &
Read More